Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?
Host: Christopher P. Cannon, MD
Guest: Samuel Dagogo-Jack, MD, DSc
Have you switched your at-risk diabetes patients to an SGLT2 inhibitor? Join Drs. Christopher Cannon and Sam Dagogo-Jack as they answer key practice questions on reducing cardiovascular risk and renal dysfunction in patients with type 2 diabetes. Patients with type 2 diabetes have two to three times the risk of developing heart failure, particularly class III and IV. SGLT2 inhibitors are changing the way we address type 2 diabetes management in patients with multiple risk factors by reducing obesity, preventing renal dysfunction, and improving heart failure, which reduces heart failure hospitalizations.